Travere Therapeutics, Inc. TVTX Business Segments — Total Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Travere Therapeutics, Inc.'s business segments — total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Travere Therapeutics, Inc.'s business segments — total revenue?
- Travere Therapeutics, Inc. (TVTX) reported business segments — total revenue of $127.2M in Q1 2026.
- How has Travere Therapeutics, Inc.'s business segments — total revenue changed year-over-year?
- Travere Therapeutics, Inc.'s business segments — total revenue increased by 55.6% year-over-year, from $81.73M to $127.2M.
- What is the long-term trend for Travere Therapeutics, Inc.'s business segments — total revenue?
- Over 3 years (2022 to 2025), Travere Therapeutics, Inc.'s business segments — total revenue has grown at a 64.9% compound annual growth rate (CAGR), from $109.46M to $490.73M.
- What does business segments — total revenue mean?
- This metric represents the total gross income generated by the company's primary business segment through the sale of pharmaceutical products and therapeutic services. It serves as a key indicator of market adoption and commercial success for the company's rare disease portfolio.